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Biphenylalkylacetylhydroquinone Ethers Suppress
the Proliferation of Murine B16 Melanoma Cells
NICOLLE FERNANDES1, MANFRED JUNG2, ALI DAOUD2 and HUANBIAO MO1
1Department

of Nutrition and Food Sciences, Texas Woman's University, Denton, TX 76204, U.S.A.;
2Institute of Pharmaceutical Sciences, University of Freiburg, Germany

Abstract. Hydroquinone, an activator of caspase-9 activity via
reactive oxygen species, and farnesol, a post-translational downregulator of 3-hydroxy-3-methylglutaryl coenzyme A reductase
activity suppress the growth of murine B16 melanoma cells. Our
previous studies have shown that farnesyl-O-acetylhydroquinone
has a markedly greater growth-suppressive activity than that
predicted by the responses to the parent compounds. Perillyl
alcohol, a modulator of small G-protein activity, and biphenyl
compounds, activators of Fas-mediated death pathways, suppress
B16 growth. A similar synergistic increase in the potency of each
compound when ether-linked to acetylhydroquinone is reported.
Perillyl-O-acetylhydroquinone, biphenylethyl-O-acetylhydroquinone
and biphenylpropyl-O-acetylhydroquinone had dose-dependent
impacts on the proliferation of B16 cells with 50% inhibitory
concentration (IC50) values of 8.0, 4.2 and 1.4 Ìmol/L,
respectively. The growth-suppression effected by biphenylpropyl-Oacetylhydroquinone was accompanied by a dose-dependent arrest
at the G1/S interface of the cell cycle, an impact greater than that
previously reported for farnesyl-O-acetylhydroquinone (IC50=2.5
Ìmol/L). These new hydroquinone derivatives may have potential
in cancer chemoprevention and/or therapy.
Hydroquinone (1-5) and trans, trans-farnesol (farnesol) (6-11)
suppress the growth of neoplastically-derived cell lines (1-11)
and with less potency, the growth of cell lines derived from
normal tissues (1, 10, 11). Preclinical trials have found no impact
of the sesquiterpenoid on the growth of normal tissues (12).

Abbreviations: IC50, the concentration required to suppress the
increase in the population of cells by 50%; FBS, fetal bovine
serum; HBSS, Hanks'-balanced salt solution; MEM, Eagle's
minimum essential medium.
Correspondence to: Huanbiao Mo, Department of Nutrition and
Food Sciences, Texas Woman's University, P.O. Box 425888,
Denton, TX 76204, U.S.A. Tel: +1 940 898 2712, Fax: +1 940 898
2634, e-mail: hmo@mail.twu.edu
Key Words: Biphenylalkyl hydroquinone, cell cycle arrest, B16
melanoma.
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Caspase-dependent and caspase-independent processes
initiate apoptosis in hydroquinone-treated cells, the former
tracing to the activation of caspase-9, the latter to the
release of apoptotic proteins from mitochondrial
membranes perturbed by reactive oxygen species (5). Cells
incubated in the presence of farnesol are arrested at the
G1/S-phase of the cell cycle (13); cells escaping this arrest
undergo apoptosis (8, 14, 15). The post-transcriptional
down-regulation of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG CoA) reductase activity signaled by farnesol starves
cells of prenyl-pyrophosphate intermediates of the
mevalonate pathway that are essential for cells to move
through the cell cycle (16).
We recently evaluated the impacts of hydroquinone and
farnesol on the growth of murine B16 melanoma cells and
found respective 50% inhibitory concentration (IC50) values
of 40 and 33 Ìmol/L (17). Synthesized farnesyl-Oacetylhydroquinone (Figure 1A) proved to have a much
greater growth-suppressive activity (IC50=2.5 Ìmol/L) than
that of either parent compound. We suggest that this
increase in potency reflects the impacts of the distinct
actions of the two components.
Perillyl alcohol also suppressed the growth of
neoplastically-derived cell lines (6, 18-22), while a
preclinical trial found no impact of this cyclic
monoterpene on the growth of normal tissues (12). The
tumor-suppressive action of perillyl alcohol has been
traced to the inhibited expression (23, 24) and processing
(25) of small G-proteins.
A natural biphenyl compound, magnolol, suppressed the
growth of B16 cells in vitro (26) and in vivo (27). The sites of
the biphenyl action, the Fas-mediated death pathway, the
activation of caspases, and anti-angiogenesis (26), appear to
be distinct from the Ras farnesylation that was proposed for
perillyl alcohol (25).
In view of the dramatic increase in the efficacy achieved
with the synthesis of an agent comprised of two constituents,
each with a distinct mode of chemopreventive action, perillylO-acetylhydroquinone (Figure 1B) and two biphenylalkyl
acetylhydroquinones, biphenylethyl-O-acetylhydroquinone
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Mitsonobu type coupling (29). All compounds were characterized
for identity and purity using nuclear magnetic resonance, infrared
spectroscopy and mass spectrometry (data not shown).

Figure 1. Schematic representation of the structures of acetylhydroquinone
derivatives farnesyl-O-acetylhydroquinone (A), perillyl-O-acetylhydroquinone
(B), biphenylethyl-O-acetylhydroquinone (C) and biphenylpropyl-Oacetylhydroquinone (D).

(Figure 1C) and biphenylpropyl-O-acetylhydroquinone
(Figure 1D) were synthesized and the growth-suppressive
activity was evaluated.

Materials and Methods
Chemical synthesis. Lovastatin was a gift from Merck Research
Laboratories (Rahway, NJ, USA). Perillyl alcohol was purchased
from Aldrich (Germany). Biphenylpropanol and biphenylethanol
were synthesized by LiAlH4 reduction of the corresponding
carboxylic acids as reported for biphenylethanol (28). The acetic
acid 4-hydroxyphenyl ester was synthesized via the Bayer-Villiger
oxidation procedure (17). The ethers were synthesized by a
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Cell proliferation assay. The proliferation of murine B16 melanoma
cells was measured by using CellTiter 96® Aqueous One Solution
(Promega, Madison, WI, USA) as previously described (17). Briefly,
the B16 melanoma cells, purchased from the American Type Culture
Collection (Manassas, VA, USA) and cultured in RPMI 1640
medium (Sigma, St. Louis, MO, USA) supplemented with 10% fetal
bovine serum (FBS, Sigma) and 80 mg gentamicin/L (Sigma) at
37ÆC in a humidified atmosphere of 5% CO2, were seeded at 1000
cells/0.1 mL medium/well in 96-well tissue culture plates (Fisher
Scientific Company LLC, Houston, TX, USA). At 24 h the medium
was decanted from each well and replaced with 0.1 mL fresh
medium containing the test agents (perillyl-O-acetylhydroquinone,
biphenylethyl-O-acetylhydroquinone and biphenylpropyl-O-acetylhydroquinone) that were pre-dissolved in dimethyl sulfoxide
(DMSO). All cultures contained 1 mL/L of DMSO. Cells were
further incubated for an additional 48 h. The 72-h cell populations
were determined by adding 20 ÌL of CellTiter 96® Aqueous One
Solution to each well; plates were held in the dark at 37ÆC for 2 h
and then read at 490 nm with a SPECTRAmax® 190 multi-plate
reader with SOFTmax® PRO version 3.0 (Molecular Devices,
Sunnyvale, CA, USA). Absorbances from wells containing cell-free
medium were used as baselines and were deducted from absorbances
of other cell-containing wells.
Biphenylpropyl-O-acetylhydroquinone was subsequently reevaluated for its dose-dependent impact on B16 cell proliferation
using the Guava® ViaCount® assay (Guava Technologies Inc.,
Hayward, CA, USA). B16 cells, inoculated in 6-well plates (Fisher
Scientific) at 1x105 cells/well in 3 mL medium, were allowed to
attach for 24 h. The culture medium was then replaced with fresh
medium containing various concentrations of biphenylpropyl-Oacetylhydroquinone pre-dissolved in DMSO. Following a 48-h
incubation the B16 cells were harvested by trypsinization,
centrifuged and resuspended in 0.2 mL phosphate-buffered saline
(PBS) to which 1 ÌL Guava® ViaCount® Flex dye was added and
mixed. Following a 5-min incubation the cell suspension was
subjected to a ViaCount® assay using a Guava® EasyCyte flow
cytometer to determine the numbers of viable cells. Guava®
ViaCount® Flex contains a dual-dye to differentiate viable and
non-viable cells.
Microscopy. Photomicrographs of representative fields of monolayers
of B16 melanoma cells were obtained with a Nikon Eclipse TS 100
microscope (Nikon Corporation, Tokyo, Japan) equipped with a
Nikon Coolpix 995 digital camera (Nikon Corporation).
Cell cycle analysis. The B16 cells were seeded in 6-well plates (Fisher
Scientific) at 1x105 cells/well with 3 mL medium/well and incubated
for 24 h. The medium was then decanted and cultures replenished
with fresh medium containing biphenylpropyl-O-acetylhydroquinone
that had been dissolved in DMSO. Following an additional 24-h
incubation adherent cells were harvested by trypsinization and
pelleted by low speed centrifugation. The cell pellets (>3x104 cells)
were fixed in 1 mL 70% ethanol at 4ÆC for 60 min, washed in 1 mL
PBS and re-suspended in 400 ÌL PBS containing 0.5 mg RNAse A
(Sigma). Following gentle mixing a 10 ÌL aliquot of propidium iodide
(Sigma, 1 g/L in PBS) was added. The cells were incubated in the
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Table I. IC50 values of acetylhydroquinone derivatives in B16 melanoma
cells.

Farnesyl-O-acetylhydroquinone
Perillyl-O-acetylhydroquinone
Biphenylethyl-O-acetylhydroquinone
Biphenylpropyl-O-acetylhydroquinone

IC50 (Ìmol/L)

n

2.5±0.6a
8.0
4.2
1.4±0.3

8
2
2
6

Values are mean±SD. aMcAnally et al. (17)

dark at room temperature for 15 min and then held at 4ÆC in the
dark for flow cytometric analysis (30). Aliquots of 5x103 cells were
analyzed for DNA content using a Guava EasyCyte flow cytometer
(Guava Technologies, Inc.). The distribution of cells in the G1, S, and
G2/M-phases of the cell cycle was determined using MultiCycle AV
software (Phoenix Flow Systems, San Diego, CA, USA).
Guava Nexinì Assay for apoptosis. The B16 cells were seeded in 6well plates (Fisher Scientific) at 200,000 cells/well with 3 mL
medium/flask and incubated for 24 h. The medium was then
decanted and cultures replenished with fresh medium containing
biphenylpropyl-O-acetylhydroquinone or lovastatin pre-dissolved in
DMSO for the experimental groups and solvent only for the control
cells. Following an additional 6, 12, or 24-h incubation, the medium
was decanted and adherent cells harvested by trypsinization and
pelleted by refrigerated centrifugation at 300 g for 10 min. The cell
pellets were washed and resuspended in Nexinì buffer (Guava
Technologies, Inc.) at 1x106 cells/mL. In each well of a 96-well plate
20 ÌL of cell suspension was mixed with 2.5 ÌL of Annexin V-PE
and 2.5 ÌL of Nexin 7-amino-actinomycin D (7-AAD) solutions
according to the manufacturer's instructions (Guava Technologies,
Inc.) and kept in the dark on ice for 20 min. The plate was then
loaded into a Guava EasyCyte flow cytometer (Guava Technologies,
Inc.) and 5x103 cells per sample were analyzed by using the Guava
ExpressPlus program. Annexin V is a phospholipid-binding protein
that has high affinity for phosphatidylserine (31) translocated from
the internal face to the outer surface of cell membranes at the early
stage of apoptosis (32). 7-AAD selectively permeates late stage
apoptotic and dead cells. Therefore cells that are viable (Annexin
V- and 7-AAD-), early apoptotic (Annexin V+ and 7-AAD-) and
late apoptotic or dead (Annexin V+ and 7-AAD+) can be
separated and percentages of these cell populations quantified.
Statistics. One-way analysis of variance (ANOVA) was performed
to assess the differences between groups. Differences in means
were analyzed by Dunnett's test. Levels of significance were
designated as p<0.05.

Results
Adding the acetylhydroquinone moiety to perillyl alcohol
gave an IC50 value for perillyl-O-acetylhydroquinone of 8.0
Ìmol/L (Table I). The IC50 values estimated for the
biphenylalkyl ethers, biphenylethyl-O-acetylhydroquinone
and biphenylpropyl-O-acetylhydroquinone, were 4.2 Ìmol/L
and 1.4±0.3 Ìmol/L, respectively.

Figure 2. Representative growth curves of B16 melanoma cells showing
the concentration-dependent suppression of B16 cell proliferation by
biphenylpropyl-O-acetylhydroquinone. Cell proliferation was measured by
CellTiter 96® Aqueous One Solution (A) and Guava® ViaCount® assay
(B) after 48-h incubation. Values are mean±SD, n=3.

Figure 2A shows the concentration-dependent suppression
of the proliferation of B16 cells by biphenylpropyl-Oacetylhydroquinone, the most potent growth suppressor
among the three derivatives. There was a near linear decrease
in cell growth following a 48-h incubation as the concentration
of biphenylpropyl-O-acetylhydroquinone increased from 0 to
2.5 Ìmol/L. Biphenylpropyl-O-acetylhydroquinone induced
15%, 47% and 91% growth suppression at 0.5, 1.5 and 2.5
Ìmol/L, respectively. The growth suppression measured by
CellTiter 96® Aqueous One Solution (Figure 2A) was also
confirmed by using Guava® ViaCount® assay. At 0.25, 0.5, 1
and 2 Ìmol/L biphenylpropyl-O-acetylhydroquinone induced
growth suppression of 13%, 18%, 34%, and 54%, respectively
(Figure 2B).
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Figure 3. Concentration-dependent inhibition of B16 melanoma cell proliferation shown in photomicrographs of B16 cells after a 24-h incubation with
0 (A), 0.5 (B), 1 (C), and 2 (D and E) Ìmol/L biphenylpropyl-O-acetylhydroquinone. Morphological changes including cell elongation and rounding are
most evident in the photomicrographs with 2 Ìmol/L biphenylpropyl-O-acetylhydroquinone (D and higher magnification, E).

The photomicrographs shown in Figure 3 reflect the
impact of biphenylpropyl-O-acetylhydroquinone on B16
cells following a 24-h incubation. The untreated cells
(Figure 3A) exhibited the characteristic contact inhibitiondisabled growth of B16 melanoma cells. Increasing the
concentration of biphenylpropyl-O-acetylhydroquinone
from 0 to 2 Ìmol/L yielded a decrease in cell density and an
increase in cell rounding, morphological changes more
evident in Figure 3E under a higher magnification.
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The impact of biphenylpropyl-O-acetylhydroquinone on
the distribution of B16 cells in the cell cycle is shown in
Figure 4. Increasing the biphenylpropyl-O-acetylhydroquinone concentration resulted in major shifts in the
distribution of cells in the phases of cell cycle. The
proportion of cells in the G1-phase increased from 50 to
70.9, 74.8 and 76.7%, while concomitantly the proportion of
cells in the S-phase decreased from 42.1 to 23.4, 21.1 and
18.0%, respectively with 0, 0.5, 1, and 2 Ìmol/L

Fernandes et al: Acetylhydroquinones Suppress B16 Cell Proliferation

Figure 4. A representative analysis of the concentration-dependent impact of biphenylpropyl-O-acetylhydroquinone on the 24-h cell cycle distribution of
B16 melanoma cells. Cells incubated with 0 (A), 0.5 (B), 1 (C) or 2 (D) Ìmol/L of biphenylpropyl-O-acetylhydroquinone for 24 h were analyzed for DNA
content by flow cytometry. Values are mean±SD, n=6.

biphenylpropyl-O-acetylhydroquinone. The G1/S ratio, an
indicator of G1 arrest, increased from 1.2 for untreated cells
to 3.0, 3.5 and 4.3 for cells treated with 0.5, 1 and 2 Ìmol/L
biphenylpropyl-O-acetylhydroquinone, respectively.
The impact of biphenylpropyl-O-acetylhydroquinone was
compared with that of lovastatin, an inhibitor of HMG CoA
reductase (16), on the initiation of apoptosis in B16 cells.
The cells were incubated for 24 h in the presence of 1.4
Ìmol/L biphenylpropyl-O-acetylhydroquinone or 1.5 Ìmol/L

lovastatin. The proportions of viable, that is, adherent, cells
in the washed control, biphenylpropyl-O-acetylhydroquinone
and lovastatin cultures were 88.0, 85.8 and 82.3%,
respectively. Within the population of cells harvested after
the dead cells were washed off the plates the proportion of
early apoptotic cells did not differ between treatments
(Figure 5). The proportions of late apoptotic cells in the
control and biphenylpropyl-O-acetylhydroquinone-treated
cells were similar. The proportion of late apoptotic cells in
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Figure 5. Representative plots showing the differential impacts of biphenylpropyl-O-acetylhydroquinone and lovastatin on the initiation of apoptosis in
murine B16 melanoma cells. B16 cells were incubated with solvent only (a-d), biphenylpropyl-O-acetylhydroquinone (1.4 Ìmol/L, e-g) or lovastatin (1.5
Ìmol/L, h-j) for 6, 12 or 24 h. The percentages of early apoptotic cells (Annexin V+/7-AAD-) and late apoptotic and necrotic cells (Annxin V+/7AAD+) in each dot plot are indicated in the corresponding quadrants. Values are mean±SD, n=3.
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the lovastatin culture (16.9±2.9%) was significantly greater
than that in the control (10.7±1.3%, p<0.05). Similar
findings were observed at 6 and 12 h.

Discussion
The IC50 values reported herein for biphenylpropyl-Oacetylhydroquinone (1.4 Ìmol/L), biphenylethyl-O-acetylhydroquinone (4.2 Ìmol/L), and perillyl-O-acetylhydroquinone (8.0 Ìmol/L), fall in the same range reported
by others for terpenylquinones and terpenylhydroquinones
(33, 34). All these values are lower than those of
hydroquinone, reportedly 40 (17) to 250 Ìmol/L (3).
In the present and previous (17) studies, the relative
potencies of perillyl alcohol, geraniol and farnesol (IC50
values, 250, 160 and 33 Ìmol/L, respectively) and those of
their acetylhydroquinone derivatives (IC50 values, 8, 5.1 and
2.5 Ìmol/L, respectively) have now been evaluated. The IC50
of perillyl-O-acetylhydroquinone was 31- and 5-fold lower
than those of perillyl alcohol (250 Ìmol/L) (35) and
hydroquinone (40 Ìmol/L) (17), respectively. Acetylation of
hydroquinone ring to prevent autoxidation is reported to have
no impact on biological potency of the hydroquinone (33).
The IC50 values of biphenylethyl-O-acetylhydroquinone
(4.2 Ìmol/L) and biphenylpropyl-O-acetylhydroquinone
(1.4 Ìmol/L) were several fold lower than those reported
for the natural biphenyl, magnolol (30-100 Ìmol/L) (26)
and hydroquinone and fell on either side of that of
farnesyl-O-acetylhydroquinone (2.5 Ìmol/L) (17). The
morphological changes in the B16 cells produced by
biphenylpropyl-O-acetylhydroquinone were reminiscent of
those induced by farnesyl-O-acetylhydroquionone, which
induced cell cycle arrest at G1-phase in B16 cells (17).
Biphenylpropyl-O-acetylhydroquinone induced B16 cell cycle
arrest at G1-phase at concentrations as low as 0.5 Ìmol/L,
an impact absent in hydroquinone- or magnolol-treated cells,
but reminiscent of, though to a greater extent than, that
induced by farnesol, farnesyl derivatives (13) and lovastatin
(17). The G1/S ratio of 4.3 induced by 2 Ìmol/L
biphenylpropyl-O-acetylhydroquinone was much greater
than the 3.1 which resulted from a longer incubation with
an equal molar concentration of farnesyl-Oacetylhydroquinone (17). The essential role of mevalonate
in cell cycle progression through G1-phase was manifested
by the lovastatin-induced cell cycle arrest at G1-phase
shown by others (36) and by our previous study (17). The
basis for the biphenylpropyl-O-acetylhydroquinone-induced
G1-phase arrest remains to be determined.
Farnesol induces apoptosis in tumor cells by limiting the pool
of mevalonate-derived intermediates required for viability (37,
38); cells respond in a similar fashion to lovastatin. Consistent
with earlier reports that hydroquinone at 2-3 Ìmol/L suppresses
apoptosis (39) and caspase-3 activity (40), apoptosis was not

observed when biphenylpropyl-O-acetylhydroquinone was
applied at its IC50 value, 1.4 Ìmol/L. At levels as high as 50-75
Ìmol/L hydroquinone is capable of inducing massive apoptosis
that is dependent on (1, 3) or independent of caspase activation
(4), which is likely to be a cell type-specific event. The
biphenylpropyl-O-acetylhydroquinone-mediated
growth
suppression shown here is therefore likely to be attributable to
cell cycle arrest.
In the present study biphenylpropyl-O-acetylhydroquinone
demonstrated an IC50 of 1.4 Ìmol/L in B16 melanoma cells.
The toxicity of biphenylpropyl-O-acetylhydroquinone to normal
cells and efficacy of biphenylpropyl-O-acetylhydroquinone in
vivo remain to be investigated. Nontheless, farnesyl-Oacetylhydroquinone with a higher IC50 of 2.5 Ìmol/L in vitro
showed tumor-suppressive potential in vivo (17). BiphenylalkylO-acetylhydroquinones may hold potential in cancer
chemoprevention and/or therapy.

Acknowledgements
This study was supported by Texas Food and Fiber Commission,
Texas Woman's University Research Enhancement and Summer
Stipend Programs and Human Nutrition Research Fund.

References
1 Terasaka H, Kadoma Y, Sakagami H and Fujisawa S: Cytotoxicity
and apoptosis-inducing activity of bisphenol A and hydroquinone
in HL-60 cells. Anticancer Res 25: 2241-2248, 2005.
2 Terasaka H, Sakagami H, Hashimoto K and Fujisawa S:
Cytotoxicity and apoptosis induction of hydroquinone in human
carcinoma cells. Jpn J Oral Biol 46(Suppl): 183, 2004.
3 Terasaka H, Morshed SR, Hashimoto K, Sakagami H and
Fujisawa S: Hydroquinone-induced apoptosis in HL-60 cells.
Anticancer Res 25: 161-170, 2005.
4 Inayat-Hussain SH, Winski SL and Ross D: Differential
involvement of caspases in hydroquinone-induced apoptosis in
human leukemic HL-60 and jurkat cells. Toxicol Appl
Pharmacol 175: 95-103, 2001.
5 Inayat-Hussain SH and Ross D: Intrinsic pathway of
hydroquinone induced apoptosis occurs via both caspasedependent and caspase-independent mechanisms. Chem Res
Toxicol 18: 420-427, 2005.
6 Burke YD, Stark MJ, Roach SL, Sen SE and Crowell PL:
Inhibition of pancreatic cancer growth by the dietary
isoprenoids farnesol and geraniol. Lipids 32: 151-156, 1997.
7 Tatman D and Mo H: Volatile isoprenoid constituents of fruits,
vegetables and herbs cumulatively suppress the proliferation of
murine B16 melanoma and human HL-60 leukemia cells.
Cancer Lett 175: 129-139, 2002.
8 Miquel K, Pradines A and Favre G: Farnesol and
geranylgeraniol induce actin cytoskeleton disorganization and
apoptosis in A549 lung adenocarcinoma cells. Biochem Biophys
Res Commun 225: 869-876, 1996.
9 Melnykovych G, Haug JS and Goldner CM: Growth inhibition
of leukemia cell line CEM-C1 by farnesol: effects of
phosphatidylcholine and diacylglycerol. Biochem Biophys Res
Commun 186: 543-548, 1992.

1011

ANTICANCER RESEARCH 28: 1005-1012 (2008)
10 Adany I, Yazlovitskaya EM, Haug JS, Voziyan PA and
Melnykovych G: Differences in sensitivity to farnesol toxicity
between neoplastically- and non-neoplastically-derived cells in
culture. Cancer Lett 79: 175-179, 1994.
11 Yazlovitskaya EM and Melnykovych G: Selective farnesol toxicity
and translocation of protein kinase C in neoplastic HeLa-S3K
and non-neoplastic CF-3 cells. Cancer Lett 88: 179-183, 1995.
12 Burke YD, Ayoubi AS, Werner SR, McFarland BC, Heilman DK,
Ruggeri BA and Crowell PL: Effects of the isoprenoids perillyl
alcohol and farnesol on apoptosis biomarkers in pancreatic cancer
chemoprevention. Anticancer Res 22: 3127-3134, 2002.
13 Miquel K, Pradines A, Terce F, Selmi S and Favre G:
Competitive inhibition of choline phosphotransferase by
geranylgeraniol and farnesol inhibits phosphatidylcholine
synthesis and induces apoptosis in human lung adenocarcinoma
A549 cells. J Biol Chem 273: 26179-26186, 1998.
14 Rioja A, Pizzey AR, Marson CM and Thomas NS: Preferential
induction of apoptosis of leukaemic cells by farnesol. FEBS Lett
467: 291-295, 2000.
15 Joo JH, Liao G, Collins JB, Grissom SF and Jetten AM:
Farnesol-induced apoptosis in human lung carcinoma cells is
coupled to the endoplasmic reticulum stress response. Cancer
Res 67: 7929-7936, 2007.
16 Mo H and Elson CE: Studies of the isoprenoid-mediated
inhibition of mevalonate synthesis applied to cancer
chemotherapy and chemoprevention. Exp Biol Med (Maywood)
229: 567-585, 2004.
17 McAnally JA, Jung M and Mo H: Farnesyl-O-acetylhydroquinone
and geranyl-O-acetylhydroquinone suppress the proliferation of
murine B16 melanoma cells, human prostate and colon
adenocarcinoma cells, human lung carcinoma cells, and human
leukemia cells. Cancer Lett 202: 181-192, 2003.
18 Samaila D, Toy BJ, Wang RC and Elegbede JA: Monoterpenes
enhanced the sensitivity of head and neck cancer cells to
radiation treatment in vitro. Anticancer Res 24: 3089-3095, 2004.
19 Elegbede JA, Flores R and Wang RC: Perillyl alcohol and
perillaldehyde induced cell cycle arrest and cell death in BroTo
and A549 cells cultured in vitro. Life Sci 73: 2831-2840, 2003.
20 Shi W and Gould MN: Induction of cytostasis in mammary
carcinoma cells treated with the anticancer agent perillyl
alcohol. Carcinogenesis 23: 131-142, 2002.
21 Shi W and Gould MN: Induction of differentiation in neuro-2A
cells by the monoterpene perillyl alcohol. Cancer Lett 95: 1-6,
1995.
22 Ruch RJ and Sigler K: Growth inhibition of rat liver epithelial
tumor cells by monoterpenes does not involve Ras plasma
membrane association. Carcinogenesis 15: 787-789, 1994.
23 Holstein SA, Wohlford-Lenane CL and Hohl RJ: Isoprenoids
influence expression of Ras and Ras-related proteins.
Biochemistry 41: 13698-13704, 2002.
24 Holstein SA and Hohl RJ: Monoterpene regulation of Ras and
Ras-related protein expression. J Lipid Res 44: 1209-1215, 2003.
25 Crowell PL, Chang RR, Ren ZB, Elson CE and Gould MN:
Selective inhibition of isoprenylation of 21-26-kDa proteins by
the anticarcinogen d-limonene and its metabolites. J Biol Chem
266: 17679-17685, 1991.

1012

26 Ikeda K and Nagase H: Magnolol has the ability to induce
apoptosis in tumor cells. Biol Pharm Bull 25: 1546-1549, 2002.
27 Ikeda K, Sakai Y and Nagase H: Inhibitory effect of magnolol
on tumour metastasis in mice. Phytother Res 17: 933-937, 2003.
28 Grovenstein E Jr, Cheng YM and Carbanions X: p-Biphenyllyl
migration in reactions of 1-chloro-2-p-biphenylethane-1,1-d2
with alkali metals. J Am Chem Soc 94: 4971-4977, 1972.
29 Hughes DL: The Mitsunobu reaction. In: Organic Reactions.
Paquette LA (ed.). London: John Wiley, pp. 335-656, 1992.
30 Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi
C: A rapid and simple method for measuring thymocyte
apoptosis by propidium iodide staining and flow cytometry. J
Immunol Methods 139: 271-279, 1991.
31 Andree HA, Reutelingsperger CP, Hauptmann R, Hemker HC,
Hermens WT and Willems GM: Binding of vascular
anticoagulant alpha (VAC alpha) to planar phospholipid
bilayers. J Biol Chem 265: 4923-4928, 1990.
32 Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL
and Henson PM: Exposure of phosphatidylserine on the surface
of apoptotic lymphocytes triggers specific recognition and
removal by macrophages. J Immunol 148: 2207-2216, 1992.
33 Miguel Del Corral JM, Gordaliza M, Castro MA, Mahiques
MM, Chamorro P, Molinari A, Garcia-Gravalos MD,
Broughton HB and San Feliciano A: New selective cytotoxic
diterpenylquinones and diterpenylhydroquinones. J Med Chem
44: 1257-1267, 2001.
34 Miguel del Corral JM, Gordaliza M, Castro MA, Mahiques
MM, San Feliciano A and Garcia-Gravalos MD: Further
antineoplastic terpenylquinones and terpenylhydroquinones.
Bioorg Med Chem 6: 31-41, 1998.
35 He L, Mo H, Hadisusilo S, Qureshi AA and Elson CE:
Isoprenoids suppress the growth of murine B16 melanomas in
vitro and in vivo. J Nutr 127: 668-674, 1997.
36 Chakrabarti R and Engleman EG: Interrelationships between
mevalonate metabolism and the mitogenic signaling pathway
in T lymphocyte proliferation. J Biol Chem 266: 12216-12222,
1991.
37 Correll CC, Ng L and Edwards PA: Identification of farnesol
as the non-sterol derivative of mevalonic acid required for the
accelerated degradation of 3-hydroxy-3-methylglutarylcoenzyme A reductase. J Biol Chem 269: 17390-17393, 1994.
38 Meigs TE, Roseman DS and Simoni RD: Regulation of 3hydroxy-3-methylglutaryl-coenzyme A reductase degradation by
the nonsterol mevalonate metabolite farnesol in vivo. J Biol
Chem 271: 7916-7922, 1996.
39 Hazel BA, Baum C and Kalf GF: Hydroquinone, a bioreactive
metabolite of benzene, inhibits apoptosis in myeloblasts. Stem
Cells (Dayton, Ohio) 14: 730-742, 1996.
40 Mohr S, Zech B, Lapetina EG and Brune B: Inhibition of
caspase-3 by S-nitrosation and oxidation caused by nitric oxide.
Biochem Biophys Res Commun 238: 387-391, 1997.

Received August 1, 2007
Revised October 11, 2007
Accepted December 7, 2007

